Archana Barhate
Department of Pharmaceutics, D. Y. Patil Deemed to be University, School of Pharmacy, Nerul East, Navi Mumbai – 400706, Maharashtra, India

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

Advanced respiratory drug delivery systems from nanocarriers to intelligent inhalation technologies: revolutionizing pulmonary therapeutics Gargi Sawant; Archana Barhate
Journal of Applied Pharmaceutical Research Vol. 14 No. 5 (2026)
Publisher : Creative Pharma Assent

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.69857/joapr.v14i5.2599

Abstract

Background: Respiratory drug delivery systems (RDDS) are important for treating respiratory and systemic diseases, including asthma, chronic obstructive pulmonary disease (COPD), and pulmonary fibrosis. Pulmonary administration offers rapid drug action, targeted delivery, and avoidance of first-pass metabolism. Methodology: This review examines recent developments in RDDS, emphasizing nanotechnology-based systems such as liposomes, solid lipid nanoparticles (SLNs), and polymeric nanoparticles. The review also discusses conventional inhalation devices, including nebulizers, dry powder inhalers (DPIs), and metered-dose inhalers (MDIs). The review covers key factors affecting delivery, including particle size, aerosol dynamics, device design, mucociliary clearance, and enzymatic degradation. The authors also consider formulation and manufacturing approaches such as micronization and spray drying. Results and Discussion: Nanotechnology-based carriers offer potential advantages, including sustained drug release and improved pulmonary delivery. RDDS have applications in respiratory and infectious diseases, lung cancer, pulmonary hypertension, and inhaled vaccines and gene therapy. The review also highlights challenges related to formulation development, manufacturing, inhalation systems, and patient inhalation technique. Effective pulmonary delivery depends on appropriate formulation characteristics, aerosol behavior, device performance, and physiological conditions. These factors can influence drug deposition and therapeutic effectiveness. Conclusion: Advances in nanocarrier-based and inhalation technologies are expanding the potential of pulmonary therapeutics. Further development of effective formulations, scalable manufacturing methods, and patient-friendly inhalation systems may support improved pulmonary drug delivery.